Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

Garg, Ritu; Hussey, Christine; Ibrahim, Seham A.

doi:10.1111/j.1464-5491.2010.02950.x

Cited by 13 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, only 4 cases of pancreatitis related to sitagliptin and vildagliptin have been reported (Table 1). One patient was treated with sitagliptin for 8 weeks;17 2 other patients were switched from sitagliptin to vildagliptin 2 weeks or 6 months before;18,19 and 1 patient received combined therapy of sitagliptin and exenatide for a few weeks 20. Raschi et al reported a significant correlation between GLP-1, DPP-4 inhibitors, and pancreatitis, on the basis of the information in the FDA database 21.…”

Section: Discussionmentioning

confidence: 99%

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin

Sue

Yoshihara

Kuboki

et al. 2013

Clin Med Insights Case Rep

View full text Add to dashboard Cite

A 55-year-old Japanese man with a 3-year history of type 2 diabetes mellitus was admitted to our hospital for upper abdominal pain. Control of diabetes mellitus was good with voglibose and metformin, with sitagliptin added to this regimen 8 months prior. His pancreatic enzyme levels were elevated, and abdominal computed tomography (CT) showed diffuse pancreatic swelling with fluid accumulation and ascites of CT grade 3. The patient was diagnosed with severe acute pancreatitis. There were no obvious causes for pancreatitis except the recently administered sitagliptin. Since incretin-related drugs entered the market, the number of incretin-related drugs prescriptions rapidly increased and so did the incidence of pancreatitis. There are several reports suggesting the correlation between incretin-related drugs and pancreatitis, such as a report based on data obtained from the United States Food and Drug Administration (FDA) which revealed a significant correlation between the administration of exenatide or sitagliptin and pancreatitis. However, there also is a report that denied the evidence for such in a large cohort study. The relation between incretin based drugs and pancreatitis is still controversial.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin

Sue

Yoshihara

Kuboki

et al. 2013

Clin Med Insights Case Rep

View full text Add to dashboard Cite

show abstract

“…There have been six published case reports of pancreatitis attributed to GLP‐1‐dependent diabetic therapies, including DPP‐IV inhibitors as well as synthetic GLP‐1 receptor agonists such as exenatide . In response to pancreatitis reported in post‐marketing surveillance through the Adverse Event Reporting System (AERS), the FDA has issued revised prescribing information for sitagliptin stating that cases of acute pancreatitis have been reported with use, to monitor closely for signs and symptoms of pancreatitis, and to use sitagliptin with caution in patients with a history of pancreatitis .…”

Section: Discussionmentioning

confidence: 99%

Sitagliptin‐induced pancreatitis – a longer road than expected

Nelson

Bhandari

Wener

2014

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

Cited by 13 publications

References 3 publications

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin

Sitagliptin‐induced pancreatitis – a longer road than expected

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About